Glucotrack Appoints Erin Carter to Board

Rutherford, NJ, Aug. 31, 2023 (GLOBE NEWSWIRE) — Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on glucose monitoring technologies for people with diabetes and prediabetes, announced today that it has appointed Erin Carter to its Board of Directors and as Chair of its Audit Committee, effective immediately.

Ms. Carter brings 30 years of executive level finance experience in the medical device industry. From 2012 until March of 2023, she held various senior roles with Medtronic, most recently serving as Chief Financial Officer and Vice President of Finance for their $9B Neuroscience division. In addition, during her tenure at Medtronic she grew the Gastrointestinal Solutions division from early tech start-up acquisition of $36M to revenue of $450M in 5 years through organic growth and multiple acquisitions. Prior to Medtronic, Ms. Carter served as Director of Finance at Boston Scientific and as VP of Accounting and Reporting at UnitedHealth Group. Prior to that, she served as Assistant Controller for Arterial Vascular Engineering, where she was instrumental in guiding the rapid growth of the company from 200 employees to over 4,000 in under five years. During this time, she managed the integration of two acquisitions and subsequently the company’s sale to Medtronic.

Ms. Carter holds a B.S. in Business Administration from California Polytech State University and is a Certified Public Accountant (inactive) in the State of California.

“We are delighted to have Erin join our Board of Directors,” said Paul Goode, CEO of Glucotrack. “She brings a wealth of financial knowledge and expertise in working with young companies and guiding them through strategic growth and expansion. She will be a tremendous asset as we look ahead to growing the organization and moving into the commercialization phase.”

“I am excited to join the Glucotrack board at such a pivotal time in the Company’s evolution,” said Ms. Carter. “I look forward to working with the Company’s leadership team to advance its mission of developing and commercializing innovative technologies to improve the lives of people with diabetes and to build long-term value for shareholders.”

About Glucotrack, Inc.

Glucotrack, Inc. (NASDAQ: GCTK), (formerly known as Integrity Applications, Inc.) is focused on the design, development, and commercialization of novel technologies for people with diabetes and prediabetes. The Company’s initial product, Glucotrack®, is a proprietary non-invasive glucose monitoring device designed to obtain glucose level measurements without the pain, incremental cost, difficulty, or discomfort of conventional invasive finger stick devices. For more information, please visit and